サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784041

糖尿病予備軍の世界市場

Prediabetes

出版日
ページ情報
英文 287 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
糖尿病予備軍の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

糖尿病予備軍の世界市場は2030年までに2億9,130万米ドルに達する見込み

2024年に2億1,010万米ドルと推定される糖尿病予備軍の世界市場は、2030年には2億9,130万米ドルに達し、分析期間2024-2030年のCAGRは5.6%で成長すると予測されます。本レポートで分析したセグメントの1つであるジグアナイド薬は、CAGR 7.2%を記録し、分析期間終了時には7,810万米ドルに達すると予測されます。チアゾリジン系薬剤セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は5,730万米ドルと推定、中国はCAGR 9.1％で成長すると予測

米国の糖尿病予備軍市場は2024年に5,730万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 9.1%で推移し、2030年には予測市場規模5,950万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.6%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の糖尿病予備軍市場- 主要動向と促進要因のまとめ

糖尿病予備軍が公衆衛生の主要な関心事になりつつあるのはなぜか？

糖尿病予備軍は、2型糖尿病の閾値に達していない血糖値の上昇を特徴とする疾患であり、世界の健康上の大きな課題として浮上しています。ライフスタイルの変化、食生活の乱れ、肥満率の増加が代謝異常の原因となっており、糖尿病予備軍の有病率は憂慮すべき速さで上昇しています。糖尿病予備軍を持つ人は、早期に介入策を実施しなければ、2型糖尿病、心血管疾患、その他の代謝性合併症を発症するリスクが著しく高くなります。この疾患は無症状であることが多く、診断の遅れや治療の遅れを招き、疾患進行のリスクを高めています。政府やヘルスケア機関は、増加する糖尿病予備軍の負担を抑制するために、早期スクリーニングプログラムや生活習慣介入イニシアチブを優先しています。さらに、持続グルコースモニタリング（CGM）、ウェアラブルヘルス技術、AI主導の予測分析の進歩により、早期発見と個別化された管理戦略が可能となっています。ヘルスケアシステムが予防医療へとシフトする中、糖尿病予備軍管理は、世界中の糖尿病予防戦略において重要な重点分野となりつつあります。

糖尿病予備軍の効果的な管理を妨げる課題とは？

意識の高まりにもかかわらず、糖尿病予備軍の効果的な管理と予防を妨げている課題がいくつかあります。最大の障壁のひとつは、定期的なスクリーニングが行われていないことです。中低所得国では、安価な診断ツールやプライマリーヘルスケアサービスへのアクセスが限られていることが、この問題をさらに悪化させています。さらに、食事、運動、体重管理などの生活習慣改善プログラムに対する患者のアドヒアランスは、行動的、社会経済的要因のために依然として大きな課題です。また、標準化された糖尿病予備軍治療ガイドラインがないため、医療勧告に一貫性がなく、ヘルスケアプロバイダーが統一された予防戦略を実施することが困難です。さらに、製薬業界はまだ糖尿病予備軍に特化した広く受け入れられる薬理学的介入を開発しておらず、ほとんどの治療アプローチは生活習慣の改善や糖尿病治療薬の適応外使用に頼っています。このような課題に対処するには、公衆衛生の取り組み、患者教育の改善、長期的なアドヒアランスと疾病予防を強化するためのデジタルヘルスソリューションの統合を組み合わせる必要があります。

デジタルヘルスとAIの革新は、糖尿病予備軍管理をどのように変革するか？

技術の進歩は糖尿病予備軍の管理に革命をもたらし、早期発見、モニタリング、個別化された介入のための革新的なソリューションを提供しています。AIを活用した予測モデルにより、ヘルスケアプロバイダーは遺伝的、代謝的、ライフスタイル的要因に基づいて2型糖尿病発症リスクの高い個人を特定できるようになっています。ウェアラブル・グルコース・モニター、フィットネストラッカー、モバイルヘルス（mヘルス）アプリケーションの統合により、血糖値、身体活動、食習慣に関するリアルタイムのデータが提供され、患者は積極的な対策を講じることができます。行動コーチングとAI主導の洞察を組み合わせたデジタル・セラピューティクスは、個別化されたライフスタイルの推奨と習慣形成介入を提供し、糖尿病予備軍管理で人気を集めています。さらに、遠隔医療はヘルスケア専門家へのアクセスを拡大し、特にサービスが行き届いていない地域で、糖尿病予備軍患者の遠隔モニタリングや診察を可能にしています。デジタルヘルス技術の進歩に伴い、糖尿病予備軍管理はよりデータ主導型の患者中心のアプローチに移行しつつあり、早期介入戦略を改善し、疾患の進行率を低下させています。

糖尿病予備軍市場の成長の原動力は？

糖尿病予備軍市場の成長は、糖尿病有病率の上昇、早期発見ソリューションに対する需要の増加、デジタルヘルス技術の進歩など、いくつかの要因によって牽引されています。予防ヘルスケアと早期介入を重視する傾向が強まっており、スクリーニングプログラム、ウェアラブル健康機器、AI主導型診断への投資が活発化しています。製薬会社は糖尿病予備軍に的を絞った治療法を開発するために新たな治療戦略を模索しており、市場機会はさらに拡大しています。また、糖尿病管理に関連する長期的なヘルスケアコストの削減に組織が注力していることから、雇用主がスポンサーとなるウェルネスプログラムや、ライフスタイルの改善イニシアチブに対する保険優遇措置の増加も市場成長に寄与しています。さらに、啓発キャンペーンやヘルスケア補助金を通じて糖尿病予防を推進する政府の取り組みも、スクリーニングや生活習慣介入プログラムの導入率を加速させています。世界のヘルスケア情勢が個別化医療や予防医療へとシフトする中、糖尿病予備軍市場は大きく拡大し、早期の代謝性疾患管理におけるイノベーションを促進すると予想されます。

セグメント

薬剤クラス（ジグアナイド薬、チアゾリジン系薬剤、グルカゴン様ペプチド-1作動薬、SGLT2阻害薬、DPP-4阻害薬、その他の薬剤クラス）、年齢層（成人、高齢者、小児）

調査対象企業の例

  • Abbott Laboratories
  • Aphaia Pharma
  • AstraZeneca PLC
  • Boston Therapeutics
  • Caelus Health
  • CH Boehringer Sohn AG & Co KG
  • Corcept Therapeutics
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • HighTide Biopharma Pty Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health
  • Pfizer Inc.
  • RESVERLOGIX
  • SciMar Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valbiotis

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32673

Global Prediabetes Market to Reach US$291.3 Million by 2030

The global market for Prediabetes estimated at US$210.1 Million in the year 2024, is expected to reach US$291.3 Million by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diguanide Drugs, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$78.1 Million by the end of the analysis period. Growth in the Thiazolidinediones Drugs segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$57.3 Million While China is Forecast to Grow at 9.1% CAGR

The Prediabetes market in the U.S. is estimated at US$57.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$59.5 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Prediabetes Market - Key Trends & Drivers Summarized

Why Is Prediabetes Becoming a Major Public Health Concern?

Prediabetes, a condition characterized by elevated blood sugar levels that have not yet reached the threshold for type 2 diabetes, is emerging as a major global health challenge. With lifestyle changes, poor dietary habits, and increasing obesity rates contributing to metabolic disorders, the prevalence of prediabetes is rising at an alarming rate. Individuals with prediabetes are at a significantly higher risk of developing type 2 diabetes, cardiovascular diseases, and other metabolic complications if intervention measures are not implemented early. The condition is often asymptomatic, leading to underdiagnosis and delayed treatment, which exacerbates the risk of disease progression. Governments and healthcare organizations are prioritizing early screening programs and lifestyle intervention initiatives to curb the growing burden of prediabetes. Additionally, advances in continuous glucose monitoring (CGM), wearable health technologies, and AI-driven predictive analytics are enabling earlier detection and personalized management strategies. As healthcare systems shift toward preventive medicine, prediabetes management is becoming a key focus area in diabetes prevention strategies worldwide.

What Challenges Are Hindering the Effective Management of Prediabetes?

Despite increasing awareness, several challenges hinder the effective management and prevention of prediabetes. One of the biggest barriers is the lack of routine screening, as many individuals remain undiagnosed until the condition progresses to type 2 diabetes. Limited access to affordable diagnostic tools and primary healthcare services in low- and middle-income countries further exacerbates the issue. Additionally, patient adherence to lifestyle modification programs, including diet, exercise, and weight management, remains a significant challenge due to behavioral and socio-economic factors. The absence of standardized prediabetes treatment guidelines also creates inconsistencies in medical recommendations, making it difficult for healthcare providers to implement uniform prevention strategies. Moreover, the pharmaceutical industry has yet to develop a widely accepted pharmacological intervention specifically for prediabetes, with most treatment approaches relying on lifestyle modifications and off-label use of diabetes medications. Addressing these challenges requires a combination of public health initiatives, improved patient education, and integration of digital health solutions to enhance long-term adherence and disease prevention.

How Are Innovations in Digital Health and AI Transforming Prediabetes Management?

Technological advancements are revolutionizing the management of prediabetes, offering innovative solutions for early detection, monitoring, and personalized intervention. AI-powered predictive models are enabling healthcare providers to identify individuals at high risk of developing type 2 diabetes based on genetic, metabolic, and lifestyle factors. The integration of wearable glucose monitors, fitness trackers, and mobile health (mHealth) applications is providing real-time data on blood sugar levels, physical activity, and dietary habits, empowering patients to take proactive measures. Digital therapeutics, which combine behavioral coaching with AI-driven insights, are gaining traction in prediabetes management, offering personalized lifestyle recommendations and habit-forming interventions. Additionally, telemedicine is expanding access to healthcare professionals, allowing remote monitoring and consultations for prediabetic patients, particularly in underserved regions. With advancements in digital health technology, prediabetes management is shifting toward a more data-driven, patient-centric approach, improving early intervention strategies and reducing disease progression rates.

What Is Driving the Growth of the Prediabetes Market?

The growth in the prediabetes market is driven by several factors, including rising diabetes prevalence, increasing demand for early detection solutions, and advancements in digital health technology. The growing emphasis on preventive healthcare and early intervention is fueling investments in screening programs, wearable health devices, and AI-driven diagnostics. Pharmaceutical companies are exploring novel therapeutic strategies to develop targeted treatments for prediabetes, further expanding market opportunities. The rise of employer-sponsored wellness programs and insurance incentives for lifestyle modification initiatives is also contributing to market growth, as organizations focus on reducing long-term healthcare costs associated with diabetes management. Additionally, government initiatives promoting diabetes prevention through public awareness campaigns and healthcare subsidies are accelerating adoption rates for prediabetes screening and lifestyle intervention programs. As the global healthcare landscape shifts toward personalized and preventive medicine, the prediabetes market is expected to expand significantly, driving innovation in early-stage metabolic disease management.

SCOPE OF STUDY:

The report analyzes the Prediabetes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs, Other Drug Classes); Age Group (Adults, Elderly, Children)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Aphaia Pharma
  • AstraZeneca PLC
  • Boston Therapeutics
  • Caelus Health
  • CH Boehringer Sohn AG & Co KG
  • Corcept Therapeutics
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • HighTide Biopharma Pty Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health
  • Pfizer Inc.
  • RESVERLOGIX
  • SciMar Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valbiotis

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Prediabetes - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Lifestyle Diseases Throws the Spotlight on Early-Stage Metabolic Disorders
    • Growing Public Health Focus on Diabetes Prevention Drives Adoption of Prediabetes Screening Programs
    • Increasing Prevalence of Obesity and Sedentary Lifestyles Spurs Growth in At-Risk Population Segments
    • Integration of Digital Health Platforms Strengthens Business Case for Scalable Prediabetes Management Solutions
    • Expansion of Remote Patient Monitoring Technologies Accelerates Demand for Continuous Glucose Tracking
    • Advancements in Predictive Analytics and Risk Stratification Tools Drive Early Detection and Intervention
    • Government-Led Awareness Campaigns and Health Screenings Propel Growth in Preemptive Diagnostics
    • Emergence of Mobile Apps and Virtual Coaching Programs Expands Addressable Market for Lifestyle Interventions
    • Rising Consumer Demand for Personalized Nutrition and Wellness Drives Innovation in Preventive Therapies
    • Growth in Employer-Sponsored Wellness Programs Strengthens Preventive Care Access for Working Adults
    • Increased Investment in Non-Invasive Biomarker Research Generates Opportunities for Early Diagnosis
    • Development of Integrated Care Models Drives Adoption of Multidisciplinary Prediabetes Management Pathways
    • Expansion of Digital Therapeutics for Metabolic Syndrome Accelerates Evidence-Based Behavioral Modification
    • Growing Insurance Coverage for Preventive Health Services Spurs Uptake of Prediabetes Screening and Counseling
    • Emergence of AI-Based Decision Support Systems Enhances Clinical Accuracy in Prediabetes Risk Profiling
    • Heightened Focus on Ethnic and Genetic Risk Factors Expands Market for Population-Specific Prevention Strategies
    • Regulatory Encouragement for Chronic Disease Prevention Strengthens Funding for Early-Intervention Programs
    • Adoption of Real-World Evidence Frameworks Drives Longitudinal Studies in Prediabetes Outcome Analysis
    • Rise of Hybrid Healthcare Delivery Models Expands Access to Rural and Underserved Populations
    • Growing Pipeline of Early-Stage Metabolic Therapeutics Drives Innovation in Pharmacological Prevention
    • Expansion of Interoperable Health IT Systems Supports Data Integration Across Prediabetes Care Continuum
    • Challenges in Long-Term Behavioral Adherence Create Market Demand for Engagement-Driven Digital Tools
    • Increased Emphasis on Social Determinants of Health Spurs Community-Based Prediabetes Prevention Initiatives
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prediabetes Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prediabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diguanide Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diguanide Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Diguanide Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Thiazolidinediones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Thiazolidinediones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Thiazolidinediones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for SGLT2 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for SGLT2 Inhibitors Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for DPP-4 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for DPP-4 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for DPP-4 Inhibitors Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Elderly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Elderly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Elderly by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • JAPAN
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • CHINA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • EUROPE
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prediabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • FRANCE
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • GERMANY
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Prediabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • INDIA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Prediabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Prediabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • AFRICA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030

IV. COMPETITION